Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis
Sign Up to like & getrecommendations! Published in 2017 at "PharmacoEconomics"
DOI: 10.1007/s40273-017-0526-0
Abstract: ObjectivesThe aim of this study was to quantify the value of conducting additional research and reducing uncertainty regarding the cost effectiveness of allopurinol and febuxostat for the management of gout.MethodsWe used a previously developed Markov… read more here.
Keywords: information; dose escalation; study; value ... See more keywords
Integrated in silico – in vitro strategy for the discovery of potential xanthine oxidase inhibitors from Egyptian propolis and their synergistic effect with allopurinol and febuxostat
Sign Up to like & getrecommendations! Published in 2022 at "RSC Advances"
DOI: 10.1039/d1ra08011c
Abstract: Xanthine oxidase (XO) has been well-recognized as a validated target for the treatment of hyperuricemia and gout. Currently, there are two drugs in clinical use that shut down XO overactivity, allopurinol and febuxostat; however, detrimental… read more here.
Keywords: allopurinol febuxostat; xanthine oxidase; strategy; egyptian propolis ... See more keywords
Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients
Sign Up to like & getrecommendations! Published in 2019 at "Renal Failure"
DOI: 10.1080/0886022x.2019.1632717
Abstract: Abstract The aim of this study was to evaluate the efficacy and tolerability of febuxostat in renal transplant recipients who were previously treated with allopurinol (the daily oral dose is 100 mg). A 6-month cohort study… read more here.
Keywords: allopurinol febuxostat; transplant recipients; efficacy; treatment ... See more keywords
Confounding by indication and ethnicity difference? Comment on ‘Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data’
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-218056
Abstract: We read with great interest the study by Singh and Cleveland1 that investigated the risk of hypersensitivity reactions (HRs) with allopurinol and febuxostat using Medicare claims data. These authors analysed a national cohort in the… read more here.
Keywords: febuxostat; medicare claims; using medicare; claims data ... See more keywords
POS1128 COMBINATION TREATMENT OF AR882, A NEW URAT1 INHIBITOR, AND XANTHINE OXIDASE INHIBITORS ALLOPURINOL OR FEBUXOSTAT: EFFECT ON URIC ACID, HYPOXANTHINE AND XANTHINE IN PLASMA OR SERUM AND URINE
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.1215
Abstract: Xanthine oxidase inhibitors (XOI) are commonly used as urate lowering therapy (ULT) for the treatment of gout. Allopurinol, the first-line treatment, demonstrates low response rate (< 40%), defined as serum urate (sUA) lowering effect below… read more here.
Keywords: allopurinol febuxostat; combination; xanthine; treatment ... See more keywords
Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0264627
Abstract: Background Although hyperuricemia is associated with chronic kidney disease, whether and how it should be managed for renoprotection remains debatable. Thus, we investigated whether allopurinol and febuxostat, the most frequently used urate-lowering treatments, have differential… read more here.
Keywords: disease; chronic kidney; allopurinol febuxostat; kidney disease ... See more keywords